One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The Anchor Strategy — A Place-Based Business Approach for Health Equity
David A. Ansell, M.D., M.P.H., Kaitlyn Fruin, M.D., Redia Holman, Ayesha Jaco, M.A.M., Bich Ha Pham, J.D., and David Zuckerman, M.P.P.
doi : 10.1056/NEJMp2213465
Corporate Investors in Primary Care — Profits, Progress, and Pitfalls
Soleil Shah, M.Sc., Hayden Rooke-Ley, B.A., and Erin C. Fuse Brown, J.D., M.P.H.
doi : 10.1056/NEJMp2212841
When Weight Impacts Health
Louis J. Aronne, M.D., Sarah Bramblette, Julie R. Ingelfinger, M.D., Ania M. Jastreboff, M.D., Ph.D., Sriram Machineni, M.D., Ph.D., Nikki Massie, and Clifford J. Rosen, Ph.D.
doi : 10.1056/NEJMp2215794
Progression of Atrial Fibrillation after Cryoablation or Drug Therapy
Atrial fibrillation is a chronic, progressive disorder, and persistent forms of atrial fibrillation are associated with increased risks of thromboembolism and heart failure. Catheter ablation as initial therapy may modify the pathogenic mechanism of atrial fibrillation and alter progression to persistent atrial fibrillation.
doi : 10.1056/NEJMoa2212540
Empagliflozin in Patients with Chronic Kidney Disease
The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.
doi : 10.1056/NEJMoa2204233
Deep Intronic FGF14 GAA Repeat Expansion in Late-Onset Cerebellar Ataxia
David Pellerin, M.D., Matt C. Danzi, Ph.D., Carlo Wilke, M.D., Mathilde Renaud, M.D., Ph.D., Sarah Fazal, Ph.D., Marie-Josée Dicaire, B.Sc., Carolin K. Scriba, B.Sc., Catherine Ashton, M.B., B.S., Christopher Yanick, B.S., Danique Beijer, Ph.D., Adriana Rebelo, Ph.D., Clarissa Rocca, M.Sc.,
doi : 10.1056/NEJMoa2207406
We sequenced the genomes of six persons with autosomal dominant LOCA who were members of three French Canadian families and identified a candidate pathogenic repeat expansion.
The Safety of Inpatient Health Care
David W. Bates, M.D., David M. Levine, M.D., M.P.H., Hojjat Salmasian, M.D., Ph.D., M.P.H., Ania Syrowatka, Ph.D., David M. Shahian, M.D., Stuart Lipsitz, Sc.D., Jonathan P. Zebrowski, M.D., M.H.Q.S., Laura C. Myers, M.D., M.P.H., Merranda S. Logan, M.D., M.P.H., Christopher G. Roy, M.D., M.P.H., Christine Iannaccone, M.P.H., Michelle L. Frits, B.A.,
doi : 10.1056/NEJMsa2206117
Adverse events during hospitalization are a major cause of patient harm, as documented in the 1991 Harvard Medical Practice Study. Patient safety has changed substantially in the decades since that study was conducted, and a more current assessment of harm during hospitalization is warranted.
Primary Ovarian Insufficiency
Cynthia A. Stuenkel, M.D., and Anne Gompel, M.D., Ph.D.
doi : 10.1056/NEJMcp2116488
Calcium Polystyrene Sulfonate–Related Colonic Necrosis
Ren-Hao Chan, M.D., and Wei-Hung Lin, M.D., Ph.D.
doi : 10.1056/NEJMicm2205643
Case 1-2023: A 49-Year-Old Man with Hypokalemia and Paranoia
Chad W. Vokoun, M.D., Mark C. Murphy, M.D., Kerry L. Reynolds, M.D., and Melanie S. Haines, M.D.
doi : 10.1056/NEJMcpc2211366
First-Line Catheter Ablation for Paroxysmal Atrial Fibrillation — Have We Reached the Tipping Point?
Roopinder K. Sandhu, M.D., M.P.H., and Christine M. Albert, M.D., M.P.H.
doi : 10.1056/NEJMe2214425
Chronic Kidney Disease — Another Step Forward
Phyllis August, M.D., M.P.H.
doi : 10.1056/NEJMe2215286
Constancy of Purpose for Improving Patient Safety — Missing in Action
Donald M. Berwick, M.D., M.P.P.
doi : 10.1056/NEJMe2213567
Audio Interview: Covid-19 Vaccines and New Viral Variants
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2300211
Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
doi : 10.1056/NEJMc2214293
Physician-Delegated Unobserved Induction with Buprenorphine in Pharmacies
doi : 10.1056/NEJMc2208055
